• Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Cision Canada
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • Analytics
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • Analytics
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Health Canada approves OFEV™ (nintedanib) for the treatment of idiopathic pulmonary fibrosis


News provided by

Boehringer Ingelheim (Canada) Ltd.

Jul 06, 2015, 07:59 ET

Share this article

Share this article


New treatment option provides hope for Canadians living with fatal lung disease

BURLINGTON, ON, July 6, 2015 /CNW/ - Boehringer Ingelheim (Canada) Ltd. announced today that on June 24, 2015 Health Canada approved OFEV™ (nintedanib) to treat idiopathic pulmonary fibrosis (IPF) in adults.1 OFEV™ has been clinically proven to reduce the decline in lung function in IPF patients.2,3

IPF is a debilitating and fatal lung disease, which causes progressive, irreversible scarring of the lungs, resulting in lung function decline and difficulty breathing.4,5 There is no cure.6 There are approximately 5,000 to 15,000 Canadians currently living with IPF, and the approval of OFEV™ offers IPF patients a new treatment option to manage this fatal disease.7,8,9

"The approval of OFEV™ is a significant advancement for IPF patients, offering a proven treatment option to people living with this disease," says Dr. Martin Kolb, M.D. PhD, Director, Division of Respirology at McMaster University. "Not only does OFEV™ offer another treatment choice for IPF patients to manage their disease, it has been shown to significantly reduce the risk of adjudicated acute exacerbations, which can be deadly."

The symptoms of IPF – shortness of breath, dry hacking cough, "crackling" sounds in the lungs, and cyanosis (blue lips) – can have a significant impact on quality of life, and make it difficult to perform everyday activities.10,11 The median survival rate for people with IPF is two to three years after diagnosis; however, early and accurate diagnosis can help to ensure access to appropriate care.12

"The Canadian Pulmonary Fibrosis Foundation welcomes the approval of OFEV™ as a new treatment option for IPF. Every advancement in treatment brings us one step closer to finding a cure, and putting an end to early death from IPF," says Robert Davidson, President, Canadian Pulmonary Fibrosis Foundation (CPFF). "We must now support efforts to ensure that Canadians have full and timely access to this treatment in a disease area with few choices."

About OFEV™ (nintedanib)

The approval of OFEV™ is based on the results from the replicate Phase III INPULSIS™ trials, involving 1,066 patients from 24 countries. Primary endpoint results showed that OFEV™ significantly reduced the annual rate of decline in lung function by approximately 50 per cent in a broad range of IPF patient types (for INPULSIS™-1, 95% CI: 77.7, 172.8, p-value <0.0001 and for INPULSIS™-2, 95% CI: 44.8, 142.7, p-value = 0.0002).1,2

OFEV™ has been shown to reduce the risk of adjudicated acute exacerbations, a secondary endpoint for INPULSIS™-1 (hazard ratio (HR) 0.55 [95% CI: 0.20, 1.54]) and for INPULSIS™-2 (HR 0.20 [95% CI: 0.07, 0.56]).1,2 This can be critical given that approximately 50 per cent of patients hospitalized for an adjudicated IPF exacerbation die during hospitalization.13

Further, there was a significant benefit of OFEV™ versus placebo in change in Saint George's Respiratory Questionnaire (SGRQ) total score in INPULSIS™-2, but no significant difference between groups in INPULSIS™-1.2 SGRQ is a self-administered questionnaire that is used to assess health-related quality of life.2

OFEV™ is administered orally by one capsule taken twice-daily.1 The most frequently reported adverse events associated with the use of OFEV™ included diarrhea, nausea and vomiting, abdominal pain, decreased appetite, weight decreased and hepatic enzyme increased.1

Boehringer Ingelheim (Canada) Ltd.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs more than 550 people across Canada. For more information please visit www.boehringer-ingelheim.ca.

-----------------------------------------

1 OFEV Product Monograph. June 24, 2015.

2 Richeldi L, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370:2071-82.

3 Richeldi L, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079-1087.

4 Collard H, et al. Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2007;176:636–643.

5 The Lung Association. Idiopathic Pulmonary Fibrosis: Overview. http://www.lung.ca/lung-health/lung-disease/idiopathic-pulmonary-fibrosis. Accessed April 2015.

6 The Canadian Pulmonary Fibrosis Foundation. Treatment & Care. http://www.canadianpulmonaryfibrosis.ca/about-pulmonary-fibrosis/treatment-and-care/. Accessed May 2015.

7 The Lung Association. Idiopathic Pulmonary Fibrosis: Treatment. http://www.lung.ca/lung-health/lung-disease/idiopathic-pulmonary-fibrosis/treatment. Accessed April 2015.

8 Raghu G. Weycker D. Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174(7):810-816.

9 Statistics Canada. Population of Canada. http://www.statcan.gc.ca/start-debut-eng.html. Accessed April 2015.

10 Shapera, S. Idiopathic Pulmonary Fibrosis (IPF). University Health Network. http://www.uhn.ca/docs/HealthInfo/Shared%20Documents/Idiopathic_pulmonary_fibrosis_IPF.pdf. Accessed April 2015.

11 The Canadian Pulmonary Fibrosis Foundation. Idiopathic pulmonary fibrosis (IPF). Accessed May 2015. http://www.canadianpulmonaryfibrosis.ca/wordpress/wp-content/uploads/2009/11/IPF-fact-sheet-FINAL-September-7-2012.pdf

12 Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.

13 Song JW, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37:356-363.

SOURCE Boehringer Ingelheim (Canada) Ltd.

Video with caption: "IPF causes progressive and permanent scarring of the lungs, and over time it becomes difficult to take a deep breath. Dr. Martin Kolb explains.". Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20150706_C5747_VIDEO_EN_433538.mp4&posterurl=http%3a%2f%2fphotos.newswire.ca%2fimages%2f20150706_C5747_PHOTO_EN_433538.jpg&order=1&jdd=20150706&cnum=C5747

Video with caption: "Dr. Martin Kolb, M.D. PhD, Director, Division of Respirology at McMaster University discusses acute exacerbations in IPF.". Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20150706_C5747_VIDEO_EN_433540.mp4&posterurl=http%3a%2f%2fphotos.newswire.ca%2fimages%2f20150706_C5747_PHOTO_EN_433540.jpg&order=2&jdd=20150706&cnum=C5747

Image with caption: "Idiopathic Pulmonary Fibrosis (IPF) is a progressive and rare lung disease, with no cure. To date there have been limited treatment options for the 5,000 to 15,000 Canadians currently living with the disease. (CNW Group/Boehringer Ingelheim (Canada) Ltd.)". Image available at: http://photos.newswire.ca/images/download/20150706_C5747_PHOTO_EN_433499.jpg

For further information: Jennifer Mota, Boehringer Ingelheim (Canada) Ltd., 905-631-4739, [email protected]

Modal title

Organization Profile

Boehringer Ingelheim (Canada) Ltd.

    Also from this source

  • EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

Contact Cision

  • 877-269-7890
    from 8 AM - 10 PM ET

  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2023 CNW Group Ltd. All Rights Reserved. A Cision company.